Related Experiment Video
Updated: May 17, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Advanced kidney failure and hyperuricemia
1Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1053, USA. mmurea@wakehealth.edu
Insights
Kidney failure causes uric acid (UA) buildup, increasing cardiovascular risks. This review explores UA metabolism in kidney disease and its link to heart health.
Area of Science:
- Nephrology
- Metabolic Disorders
- Cardiovascular Medicine
Background:
- Metabolic byproducts, like uric acid (UA), accumulate in kidney failure.
- Hyperuricemia (HUA) is linked to gout and increased cardiovascular (CV) morbidity/mortality, common in kidney disease patients.
- Serum UA levels increase as kidney function declines, while gout attacks decrease and CV death risk rises.
Purpose of the Study:
- To review uric acid metabolism kinetics in chronic kidney disease (CKD) and dialysis.
- To discuss potential mechanisms for gout mitigation in kidney failure.
- To explore the role of hyperuricemia in adverse CV outcomes in kidney disease.
Main Methods:
- Literature review of uric acid metabolism in CKD and dialysis.
- Analysis of factors influencing gout frequency and CV mortality in kidney disease.
- Discussion of hyperuricemic milieu's contribution to cardiovascular outcomes.
Main Results:
- Uric acid accumulation is characteristic of declining kidney function.
- Despite rising UA levels, gout attacks may decrease in advanced kidney disease.
- Hyperuricemia is increasingly associated with cardiovascular complications in kidney patients.
Conclusions:
- Understanding UA kinetics is crucial in managing kidney disease.
- Mechanisms for gout mitigation in kidney failure warrant further investigation.
- The hyperuricemic state in kidney disease may significantly contribute to cardiovascular risk.
Abstract:
Metabolic end products accumulate in kidney failure, including uric acid (UA), a terminal product of purine catabolism. Hyperuricemia (HUA) can cause gout and has been increasingly linked with cardiovascular (CV) morbidity and mortality, outcomes that are highly prevalent in patients with kidney disease. Serum UA levels rise as glomerular filtration declines, whereas the frequency of gouty attacks declines and the incidence of CV death rises precipitously. Herein, we review the kinetics of UA metabolism in CKD and dialysis and discuss the possible mechanisms of gout mitigation in kidney failure and the potential contribution of hyperuricemic milieu to CV outcomes in patients with kidney disease.
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
